OncoMatch/Clinical Trials/NCT04740424

FS222 First in Human Study in Patients With Advanced Malignancies

Is NCT04740424 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies FS222 for advanced cancer.

Phase 1RecruitinginvoX Pharma LimitedNCT04740424Data as of May 2026

Treatment: FS222 — This study will be conducted in adult participants diagnosed with advanced tumours to characterize the safety, tolerability, pharmacokinetics (PK), and activity of FS222. This is a Phase 1, multi-center, open label, multiple-dose, first in human study, designed to systematically assess safety and tolerability, and to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) for FS222 in participants with advanced tumours. Pharmacokinetics, pharmacodynamics, immunogenicity, and response will also be assessed.

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Cannot have received: CD137 agonist monoclonal antibody or other experimental agonists

Prior treatment with CD137 agonist mAb or other experimental agonists

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify